ArticleBMC pulmonary medicine2026
Mortality rate and affecting factors in bronchiectasis patients: a 10-year retrospective cohort study from Turkey.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Co-infection withFrontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiectasis is a heterogeneous respiratory disease with substantial variation in its clinical course. This study aimed to determine the all-cause mortality rate among hospitalized adults with bronchiectasis—the prespecified primary endpoint—and to evaluate secondary exploratory predictors including sputum microbiology and peripheral eosinophil counts.
methodsWe retrospectively analyzed 14,319 outpatients diagnosed with bronchiectasis (ICD-10 J47) at a tertiary care center between 2015 and 2024. Mortality analysis was restricted to 2,382 hospitalized adults. Demographic characteristics, comorbidities, hospitalization burden, sputum microbiology, and baseline eosinophil levels were assessed. Time-to-all-cause mortality was analyzed using a multivariate Cox proportional hazards model (confirmatory analysis). Associations involving microbiology and eosinophilia were evaluated as secondary exploratory endpoints.
resultsThe 10-year crude mortality rate was 34.8%, higher in males and in patients ≥ 55 years. Independent predictors of increased mortality included male sex, older age, COPD, sequelae of tuberculosis, Pseudomonas aeruginosa infection, increased hospitalization number, and longer hospital stay. Pseudomonas aeruginosa was the most frequently isolated pathogen and was associated with recurrent hospitalizations and higher mortality. Hemoptysis was associated with better survival. Baseline eosinophilia (≥300 cells/µL) was independently associated with mortality, although the effect size was minimal (HR 1.003), indicating limited clinical impact.
conclusionBronchiectasis imposes a significant mortality burden, particularly among older males and patients with COPD overlap or Pseudomonas aeruginosa infection. Hemoptysis was associated with better survival, whereas peripheral eosinophilia showed only a minimal prognostic effect. These findings highlight the clinical heterogeneity of bronchiectasis and support a risk-stratified management approach focused on high-risk phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.